Why does your RA treatment tier matter more than the diagnosis?
Simplified issue life insurance doesn't require a medical exam, but it does ask health questions. The inflammatory arthritis question on most applications asks specifically about treatment. For rheumatoid and psoriatic arthritis, the question distinguishes between NSAID or aspirin-only management and treatment that goes beyond that: biologics, DMARDs, or systemic steroids.
The logic behind that distinction is clinical. NSAIDs manage symptoms. Biologics and DMARDs modify the disease itself by suppressing immune function. That immune suppression is what underwriters are assessing, not the arthritis per se. A biologic prescription signals that the disease is more active, harder to control with simpler means, and carries a different long-term risk profile than naproxen taken for joint pain.
This is also why disclosing your medication accurately matters. An application that omits a biologic prescription and later faces a claim can be voided for misrepresentation. The underwriter's view of Humira is generally less alarming than the applicant's fear of disclosing it. Hiding it causes more problems than it solves.
What are your options if you're managing RA with NSAIDs only?
At this treatment level, some simplified issue carriers in Canada take a notably positive view. Certain carriers explicitly exclude NSAID-controlled inflammatory arthritis from their question set entirely, treating it as no restriction at all for coverage eligibility or amount. For applicants in this tier with no other health conditions present, that can mean access to the full range of no-exam coverage available in the market, at rates close to what a fully healthy applicant would pay.
This is one of the more positive surprises in the simplified issue market. Many people with RA on anti-inflammatories assume the diagnosis alone limits their options. For some carriers, NSAID-controlled RA is simply not a factor at all. A licensed advisor familiar with the no-exam market can identify which carriers take this approach.
Not every carrier takes this position. Some assess the diagnosis regardless of treatment tier, particularly in the fully underwritten market. But in the simplified issue space, there is genuine variation, and finding the right carrier for this specific situation is exactly where an independent advisor adds value.
One practical note: if your treatment is stable on NSAIDs and there have been no medication changes in the last 12 months, that stability is itself a positive factor. A medication change within the last year, even a minor dosage adjustment to an existing drug, can trigger a separate medication-change question. That question doesn't change the outcome significantly at this treatment tier, but it's worth knowing.
How does being on biologics or DMARDs affect your application?
Biologics, including Humira, Enbrel, and Remicade, along with DMARDs like methotrexate, represent a more advanced treatment tier. In the fully underwritten market, these medications can result in higher premiums or rated policies depending on disease severity and stability. In the simplified issue market, the picture is generally more accessible than most applicants expect.
Most simplified issue carriers do not decline based on biologic or DMARD use alone. The typical outcome for a stable RA applicant on biologics is that access to the highest-rate no-exam category is limited, while the broader simplified issue market remains available. Both term and permanent coverage are generally accessible, with coverage amounts that can reach $500,000 or more depending on age and the specific carrier. The condition affects where in the market you land rather than whether you can access it.
Medication stability matters to underwriters. Being on the same biologic for two or more years without switching signals that the disease responds to treatment and the regimen is working. Frequent switches between biologics suggest a harder-to-control disease and tend to produce less favourable assessments. If your treatment has been stable, say so clearly on the application.
The biologics themselves, Humira, Enbrel, Remicade and others, are standard of care for moderate to severe RA. Underwriters know this. Being on one of these medications is not a red flag in isolation. What underwriters are looking for is the overall picture: stable medication, regular specialist follow-up, controlled disease activity, and no significant comorbidities.
Which comorbidities change what's available with RA?
For most RA applicants, the condition itself is manageable within the simplified issue market. The variables that can shift the outcome more significantly are conditions that sometimes develop alongside RA.
Cardiovascular disease. RA carries elevated cardiovascular risk over time. If hypertension, AFib, or other cardiac conditions are present, those are assessed independently on their own questions and timing. A cardiac history that would otherwise produce a restricted outcome does so regardless of the RA. The two are assessed separately, and whichever produces the more restrictive result governs.
Interstitial lung disease. RA-associated lung disease is less common but worth knowing about. If a chronic lung condition has been diagnosed alongside RA, the lung question applies independently and can shift the outcome. Applicants who have had any respiratory investigation related to their RA should flag this with an advisor before applying.
Recent hospitalization. A hospitalization for RA-related complications within the last 60 days would trigger the recent hospitalization question and temporarily produce the most restricted outcome. Once that window clears, the RA-specific picture applies again.
What to Bring to the Conversation
Before speaking with a licensed advisor, know the specific medications you're taking and how long you've been on them. If you've switched biologics recently, know when and why. Know whether any other conditions, particularly cardiovascular or respiratory, have come up in your care. That picture determines which carriers are worth approaching and in what order.
Know the monthly premium you're comfortable sustaining long term. And know your burden: the immediate financial exposure your death would create for the people around you. A mortgage, a dependent spouse, final expenses. Coverage amount follows from that, not from a number picked without reference to what it needs to cover.
RA on its own is rarely the obstacle people expect. The treatment tier matters, the stability of that treatment matters, and finding the right carrier for your specific picture matters. A licensed advisor familiar with the no-exam market will know where the best fit is.
This article is for educational purposes only and does not constitute insurance advice. Eligibility, premiums, and coverage terms vary by individual health profile and insurer. Speak with a licensed Canadian insurance advisor before making any coverage decision. Reviewed by a licensed Canadian insurance professional.